Want to see ORGO full AI Analyst Report?
ORGO Stock Chart & Stats
$2.39
$0.13(5.44%)
At close: 4:00 PM EDT
$2.39
$0.13(5.44%)
Day’s Range― - ―
52-Week Range$1.54 - $7.08
Previous CloseN/A
Volume86.56K
Average Volume (3M)774.97K
Market Cap
$231.61M
Enterprise Value$472.65
Total Cash (Recent Filing)$46.10M
Total Debt (Recent Filing)$66.95M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Nov 05, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding128,674,550
10 Day Avg. Volume804,336
30 Day Avg. Volume774,972
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.51
Price to Sales (P/S)1.17
P/FCF Ratio-26.84
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$2.00Price Target Upside-16.32% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-1.38
Revenue Forecast (FY)$196.05M
Bulls Say, Bears Say
Bulls Say
Strengthening Clinical EvidenceA broad and growing clinical evidence base can support physician adoption, payer coverage and durable differentiation in chronic wound care, potentially improving the company’s ability to defend and expand product utilization over time.
Regulatory Pipeline ProgressFDA acceptance advances Amnuvx toward a potential first-in-category biologic for symptomatic knee osteoarthritis, creating a longer-term growth option beyond the pressured wound-care business if approval and commercialization succeed.
Cost Restructuring And DeleveragingLarge, identified cost reductions can lower the company’s break-even point and improve operating leverage during recovery. The absence of debt also reduces interest burden and provides greater flexibility while management rebuilds profitability.
Bears Say
Severe Revenue ContractionThe scale of the revenue decline indicates a substantial demand, reimbursement or market-disruption problem rather than ordinary volatility. Lower sales reduce absorption of fixed costs and make the path to sustainable profitability materially harder.
Margin And Operating Loss PressureSharp gross-margin compression alongside widening operating losses shows that the current business model is not absorbing the revenue shock efficiently. Cost reductions may help, but restoring margins and positive earnings remains an execution-intensive challenge.
Liquidity And Dilution RiskThe cash reduction and continuing losses increase dependence on operating improvement or external financing. Using the ATM could extend liquidity, but issuing shares would dilute existing holders and signal limited internal funding capacity.
Organogenesis Holdings News
ORGO FAQ
What was Organogenesis Holdings’s price range in the past 12 months?
Organogenesis Holdings lowest stock price was $1.54 and its highest was $7.08 in the past 12 months.
What is Organogenesis Holdings’s market cap?
Organogenesis Holdings’s market cap is $231.61M.
When is Organogenesis Holdings’s upcoming earnings report date?
Organogenesis Holdings’s upcoming earnings report date is Nov 05, 2026 which is in 74 days.
How were Organogenesis Holdings’s earnings last quarter?
Organogenesis Holdings released its earnings results on Aug 06, 2026. The company reported -$0.714 earnings per share for the quarter, missing the consensus estimate of -$0.35 by -$0.364.
Is Organogenesis Holdings overvalued?
According to Wall Street analysts Organogenesis Holdings’s price is currently Overvalued.
Does Organogenesis Holdings pay dividends?
Organogenesis Holdings does not currently pay dividends.
What is Organogenesis Holdings’s EPS estimate?
Organogenesis Holdings’s EPS estimate is -0.18.
How many shares outstanding does Organogenesis Holdings have?
Organogenesis Holdings has 128,674,550 shares outstanding.
What happened to Organogenesis Holdings’s price movement after its last earnings report?
Organogenesis Holdings reported an EPS of -$0.714 in its last earnings report, missing expectations of -$0.35. Following the earnings report the stock price went down -22.822%.
Which hedge fund is a major shareholder of Organogenesis Holdings?
Currently, no hedge funds are holding shares in ORGO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Organogenesis Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.00 (-16.32% Downside)
$2.00 (-16.32% Downside)
Blogger Sentiment
Bullish
ORGO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 13.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.30%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-11.86%
Trailing 12-Months
Company Description
Organogenesis Holdings
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
ORGO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presented meaningful operational and clinical positives — sequential revenue recovery, strong clinical trial results (PuraPly AM and Affinity), FDA acceptance of the Amnuvx BLA and tangible cost-reduction measures — but these are outweighed by significant near-term financial stress: severe year-over-year revenue declines (≈58%), large operating and GAAP net losses, a halved cash position since year-end, lowered full-year revenue guidance, and deferred product launch timing to preserve cash. Management is focused on evidence-driven market share gains and expects improving adjusted EBITDA by Q4, but the company remains in a substantial recovery phase with execution and financing risks in the near term.View all ORGO earnings summariesORGO Stock 12 Month Forecast
Average Price Target
$2.00
▼(-16.32% Downside)
Technical Analysis
Ownership Overview
17.00% Insiders
7.01% Mutual Funds
11.71% Other Institutional Investors
52.27% Public Companies and
Individual Investors